HIV-associated Chronic Immune Activation

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2013 Jun 19

PMID 23772616

Citations 242

Authors

Mirko Paiardini

Michaela Muller-Trutwin

Affiliations

Soon will be listed here.

Abstract

Systemic chronic immune activation is considered today as the driving force of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS). A residual chronic immune activation persists even in HIV-infected patients in which viral replication is successfully inhibited by anti-retroviral therapy, with the extent of this residual immune activation being associated with CD4(+) T-cell loss. Unfortunately, the causal link between chronic immune activation and CD4(+) T-cell loss has not been formally established. This article provides first a brief historical overview on how the perception of the causative role of immune activation has changed over the years and lists the different kinds of immune activation characteristic of human immunodeficiency virus (HIV) infection. The mechanisms proposed to explain the chronic immune activation are multiple and are enumerated here, as well as the mechanisms proposed on how chronic immune activation could lead to AIDS. In addition, we summarize the lessons learned from natural hosts that know how to 'show AIDS the door', and discuss how these studies informed the design of novel immune modulatory interventions that are currently being tested. Finally, we review the current approaches aimed at targeting chronic immune activation and evoke future perspectives.

Citing Articles

The Role of Sustained Type I Interferon Secretion in Chronic HIV Pathogenicity: Implications for Viral Persistence, Immune Activation, and Immunometabolism.

Teer E, Mukonowenzou N, Essop M Viruses. 2025; 17(2).

PMID: 40006894 PMC: 11860620. DOI: 10.3390/v17020139.

The impact of HPV/HIV co-infection on immunosuppression, HPV genotype, and cervical cancer biomarkers.

Swase T, Fasogbon I, Eseoghene I, Etukudo E, Mbina S, Joan C BMC Cancer. 2025; 25(1):202.

PMID: 39910495 PMC: 11796042. DOI: 10.1186/s12885-025-13516-2.

SHMT2 regulates CD8+ T cell senescence via the reactive oxygen species axis in HIV-1 infected patients on antiretroviral therapy.

Zhang Q, Wang J, Yang T, Li S, Li J, Liu D EBioMedicine. 2025; 112:105533.

PMID: 39808948 PMC: 11782833. DOI: 10.1016/j.ebiom.2024.105533.

Perinatal outcomes among pregnant women with HIV initiating antiretroviral therapy preconception and antenatally.

Boering P, Murray C, Portwood C, Hey M, Thompson L, Beck K AIDS. 2025; 39(5):584-596.

PMID: 39760703 PMC: 11902611. DOI: 10.1097/QAD.0000000000004104.

Association of T-Cell Phenotypes With Peri-Coronary Inflammation in People With and Without HIV and Without Cardiovascular Disease.

Freeman M, Hossain M, Burrowes S, Jeudy J, Diaz-Mendez F, Mitchell S Circ Cardiovasc Imaging. 2024; 18(1):e017033.

PMID: 39641168 PMC: 11753945. DOI: 10.1161/CIRCIMAGING.124.017033.

References

Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B . Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011; 118(12):3263-72. DOI: 10.1182/blood-2011-01-329060. View

Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K . Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol. 2007; 34(6):1353-5. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Raffatellu M, Santos R, Verhoeven D, George M, Wilson R, Winter S . Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008; 14(4):421-8. PMC: 2901863. DOI: 10.1038/nm1743. View

Krown S, Roy D, Lee J, Dezube B, Reid E, Venkataramanan R . Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr. 2011; 59(5):447-54. PMC: 3302934. DOI: 10.1097/QAI.0b013e31823e7884. View

Schwarz A, Offermann G, Keller F, BENNHOLD I, Lage-Stehr J, Krause P . The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation--data on four cases and review of the literature. Transplantation. 1993; 55(1):95-103. DOI: 10.1097/00007890-199301000-00019. View

Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D . Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients. Viral Immunol. 2004; 17(1):109-13. DOI: 10.1089/088282404322875502. View

Salgado M, Rallon N, Rodes B, Lopez M, Soriano V, Benito J . Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. Clin Immunol. 2011; 139(2):110-4. DOI: 10.1016/j.clim.2011.02.008. View

Brown K, Trichel A, Barratt-Boyes S . Parallel loss of myeloid and plasmacytoid dendritic cells from blood and lymphoid tissue in simian AIDS. J Immunol. 2007; 178(11):6958-67. DOI: 10.4049/jimmunol.178.11.6958. View

10.

Vanderford T, Slichter C, Rogers K, Lawson B, Obaede R, Else J . Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation. Blood. 2012; 119(24):5750-7. PMC: 3382934. DOI: 10.1182/blood-2012-02-411496. View

11.

Ascher M, Sheppard H . AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol. 1988; 73(2):165-7. PMC: 1541594. View

12.

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

13.

Eggena M, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C . Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174(7):4407-14. DOI: 10.4049/jimmunol.174.7.4407. View

14.

Naarding M, Baan E, Pollakis G, Paxton W . Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007; 4:6. PMC: 1796897. DOI: 10.1186/1742-4690-4-6. View

15.

Molina J, Scadden D, Byrn R, Dinarello C, Groopman J . Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest. 1989; 84(3):733-7. PMC: 329713. DOI: 10.1172/JCI114230. View

16.

Levy Y, Sereti I, Tambussi G, Routy J, Lelievre J, Delfraissy J . Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis. 2012; 55(2):291-300. PMC: 3381639. DOI: 10.1093/cid/cis383. View

17.

Pantaleo G, Graziosi C, Demarest J, Butini L, Montroni M, Fox C . HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993; 362(6418):355-8. DOI: 10.1038/362355a0. View

18.

Estes J, Harris L, Klatt N, Tabb B, Pittaluga S, Paiardini M . Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010; 6(8):e1001052. PMC: 2924359. DOI: 10.1371/journal.ppat.1001052. View

19.

Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P . Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J Infect Dis. 2012; 207(4):622-7. DOI: 10.1093/infdis/jis732. View

20.

Chahroudi A, Bosinger S, Vanderford T, Paiardini M, Silvestri G . Natural SIV hosts: showing AIDS the door. Science. 2012; 335(6073):1188-93. PMC: 3822437. DOI: 10.1126/science.1217550. View